ePrints

Multidisciplinary considerations for implementing Bayesian borrowing in basket trials

Lookup NU author(s): Professor James WasonORCiD

Downloads

Full text for this publication is not currently held within this repository. Alternative links are provided below where available.

Abstract

© 2024 Elsevier LtdDrug development has historically relied on phase I–III clinical trials including participants sharing the same disease. However, drug development has evolved as the discovery of mechanistic drivers of disease demonstrated that the same therapeutic target may provide benefits across different diseases. A basket trial condenses evaluation of one therapy among multiple related diseases into a single trial and presents an opportunity to borrow information across them rather than viewing each in isolation. Borrowing is a statistical tool but requires a foundation of clinical and therapeutic mechanistic justification. We review the Bayesian borrowing approach, including its assumptions, and provide a framework for how this approach can be evaluated for successful use in a basket trial for drug development.

Publication metadata

Author(s): Broglio KR, Blau JE, Pilling EA, Wason JMS

Publication type: Review

Publication status: Published

Journal: Drug Discovery Today

Year: 2024

Volume: 29

Issue: 9

Print publication date: 01/09/2024

Online publication date: 02/08/2024

Acceptance date: 02/04/2024

ISSN (print): 1359-6446

ISSN (electronic): 1878-5832

Publisher: Elsevier Ltd

URL: https://doi.org/10.1016/j.drudis.2024.104127

DOI: 10.1016/j.drudis.2024.104127

PubMed id: 39098385

Share